Targets › RPGR
4 programs from 3 companies in 8 trials: 4 Phase 2, 2 Phase 1, 2 Phase 3; Ophthalmology; next expected readout Feb 2027.
Acts as a guanine-nucleotide releasing factor (GEF) for RAB8A and RAB37 by promoting the conversion of inactive RAB-GDP to the active form RAB-GTP. GEF activity towards RAB8A may facilitate ciliary trafficking by modulating ciliary intracellular localization of RAB8A. GEF activity towards RAB37 maintains autophagic homeostasis and retinal function (By similarity). Involved in photoreceptor integrity (By similarity). (UniProt, Q92834)
Open in Phaseline: the race on RPGR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| MeiraGTx Ocular UK | AAV5-hRKp.RPGR (botaretigene sparoparvovec, JNJ-74765340) AAV5-mediated RPGR gene replacement | RPGR | Phase 3 | Retinitis Pigmentosa; X-Linked Retinitis Pigmentosa | Jun 2027 |
| Beacon Therapeutics | rAAV2tYF-GRK1-RPGR Adeno-associated virus vector expressing human RPGR gene | RPGR | Phase 2 | X-Linked Retinitis Pigmentosa | Feb 2027 |
| Beacon Therapeutics | Laruparetigene zovaparvovec (AGTC-501) Adeno-associated virus vector expressing human RPGR gene | RPGR | Phase 2 | X-Linked Retinitis Pigmentosa (XLRP); X-Linked Retinitis Pigmentosa | Dec 2029 |
| 4D Molecular Therapeutics | 4D-125 AAV5-delivered codon-optimized human RPGR transgene | RPGR | Phase 1 | X-Linked Retinitis Pigmentosa | May 2029 |
X-Linked Retinitis Pigmentosa (6) Retinitis Pigmentosa (1) X-Linked Retinitis Pigmentosa (XLRP) (1)
protein or peptide (2), other (2)
Beacon Therapeutics (2) MeiraGTx Ocular UK (1) 4D Molecular Therapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.